The two biggest GLP-1 peptides compared head-to-head clinical trial data, who belongs on each protocol, and how BHRC approaches the decision
Reported pattern in community references: Months 03: body composition shifts through the deficit fat loss with some lean-mass loss expected Months 47: layering cagrilintide adds satiety without adding additional energy-expenditure mechanism body-composition trajectory continues at the prior ratio Months 7+: at maintenance, training stimulus and protein intake dominate body-composition outcomes more than the peptide stack does Whether layering SLU-PP-332 would meaningfully shift the body-composition trajectory by adding an output-side mechanism is unstudied
The peptide stimulates keratinocyte migration 2-3-fold over baseline when as little as 10 picograms is applied, demonstrating potent effects even at minimal concentrations
Cagrilintide is developed by Novo Nordisk, the same company behind semaglutide (Ozempic/Wegovy) and the CagriSema combination
Aunque no figura explcitamente en la lista de sustancias prohibidas en 2026, podra clasificarse bajo la categora de factores de crecimiento peptdicos (seccin S2 de la lista de prohibiciones)
This aspect is essential for projects requiring extended observation periods or those focused on the effects of sustained peptide administration
